Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy.
Current Medical Research and Opinion, 2016 32(5): 817-827. e-pub ahead of print 2016/01/09